0001193125-21-303072.txt : 20211020 0001193125-21-303072.hdr.sgml : 20211020 20211020161957 ACCESSION NUMBER: 0001193125-21-303072 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 12 CONFORMED PERIOD OF REPORT: 20211020 ITEM INFORMATION: Results of Operations and Financial Condition FILED AS OF DATE: 20211020 DATE AS OF CHANGE: 20211020 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Crinetics Pharmaceuticals, Inc. CENTRAL INDEX KEY: 0001658247 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 263744114 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-38583 FILM NUMBER: 211334428 BUSINESS ADDRESS: STREET 1: 10222 BARNES CANYON ROAD, BLDG. #2 CITY: SAN DIEGO STATE: CA ZIP: 92121 BUSINESS PHONE: 858-450-6464 MAIL ADDRESS: STREET 1: 10222 BARNES CANYON ROAD, BLDG. #2 CITY: SAN DIEGO STATE: CA ZIP: 92121 8-K 1 d195018d8k.htm 8-K 8-K
false 0001658247 0001658247 2021-10-20 2021-10-20

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

FORM 8-K

 

 

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): October 20, 2021

 

 

Crinetics Pharmaceuticals, Inc.

(Exact name of registrant as specified in its charter)

 

 

 

Delaware   001-38583   26-3744114

(State or Other Jurisdiction of

Incorporation or Organization)

   (Commission
File Number)		   (I.R.S. Employer
Identification Number)

10222 Barnes Canyon Road, Bldg #2

San Diego, California 92121

(858) 450-6464

(Address, Including Zip Code, and Telephone Number, Including Area Code, of Registrant’s Principal Executive Offices)

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligations of the registrant under any of the following provisions:

 

☐

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

☐

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

☐

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

☐

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class

  

Trading

Symbol(s)

  

Name of each exchange
on which registered

Common Stock, par value $0.001 per share   CRNX   Nasdaq Global Select Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR § 230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR § 240.12b-2).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☒

 

 

 

Item 2.02. Results of Operations and Financial Condition

Crinetics Pharmaceuticals, Inc. (the “Company” or “Crinetics”) estimates that its cash, cash equivalents and investments were approximately $193.4 million as of September 30, 2021. This amount is unaudited and preliminary and is subject to completion of financial closing procedures. As a result, this amount may differ from the amount that will be reflected in Crinetics’ financial statements as of and for the quarter ended September 30, 2021.

The information in this Item 2.02 shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, except as shall be expressly set forth by specific reference in such a filing.

Forward-Looking Statements

Crinetics cautions you that statements contained in this current report regarding matters that are not historical facts are forward-looking statements. These statements are based on the Company’s current beliefs and expectations. Such forward-looking statements include the Company’s estimated cash and cash equivalents as of September 30, 2021. The inclusion of forward-looking statements should not be regarded as a representation by Crinetics that any of its plans will be achieved. Actual results may differ from those set forth in this current report due to the risks and uncertainties inherent in Crinetics’ business, including, without limitation: potential changes in estimated cash and cash equivalents based on the completion of financial closing procedures and release of complete third quarter 2021 results; and other risks described under the heading “Risk Factors” in documents the Company files from time to time with the Securities and Exchange Commission. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof, and Crinetics undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date hereof. All forward-looking statements are qualified in their entirety by this cautionary statement, which is made under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995.

 

2

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

Date: October 20, 2021     Crinetics Pharmaceuticals, Inc.
   

/s/ R. Scott Struthers, Ph.D.

    R. Scott Struthers, Ph.D.
   

President and Chief Executive Officer

(Principal Executive Officer)

 

3

EX-101.SCH 2 crnx-20211020.xsd XBRL TAXONOMY EXTENSION SCHEMA 100000 - Document - Document and Entity Information link:calculationLink link:presentationLink link:definitionLink EX-101.LAB 3 crnx-20211020_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Cover [Abstract] Cover [Abstract] Amendment Flag Amendment Flag Entity Central Index Key Entity Central Index Key Document Type Document Type Document Period End Date Document Period End Date Entity Registrant Name Entity Registrant Name Entity Incorporation State Country Code Entity Incorporation State Country Code Entity File Number Entity File Number Entity Tax Identification Number Entity Tax Identification Number Entity Address, Address Line One Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Two Entity Address, City or Town Entity Address, City or Town Entity Address, State or Province Entity Address, State or Province Entity Address, Postal Zip Code Entity Address, Postal Zip Code City Area Code City Area Code Local Phone Number Local Phone Number Written Communications Written Communications Soliciting Material Soliciting Material Pre Commencement Tender Offer Pre Commencement Tender Offer Pre Commencement Issuer Tender Offer Pre Commencement Issuer Tender Offer Security 12b Title Security 12b Title Trading Symbol Trading Symbol Security Exchange Name Security Exchange Name Entity Emerging Growth Company Entity Emerging Growth Company Entity Ex Transition Period Entity Ex Transition Period EX-101.PRE 4 crnx-20211020_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE XML 5 d195018d8k_htm.xml IDEA: XBRL DOCUMENT 0001658247 2021-10-20 2021-10-20 false 0001658247 8-K 2021-10-20 Crinetics Pharmaceuticals, Inc. DE 001-38583 26-3744114 10222 Barnes Canyon Road Bldg #2 San Diego CA 92121 (858) 450-6464 false false false false Common Stock, par value $0.001 per share CRNX NASDAQ true true XML 6 R1.htm IDEA: XBRL DOCUMENT v3.21.2
Document and Entity Information
Oct. 20, 2021
Cover [Abstract]  
Amendment Flag false
Entity Central Index Key 0001658247
Document Type 8-K
Document Period End Date Oct. 20, 2021
Entity Registrant Name Crinetics Pharmaceuticals, Inc.
Entity Incorporation State Country Code DE
Entity File Number 001-38583
Entity Tax Identification Number 26-3744114
Entity Address, Address Line One 10222 Barnes Canyon Road
Entity Address, Address Line Two Bldg #2
Entity Address, City or Town San Diego
Entity Address, State or Province CA
Entity Address, Postal Zip Code 92121
City Area Code (858)
Local Phone Number 450-6464
Written Communications false
Soliciting Material false
Pre Commencement Tender Offer false
Pre Commencement Issuer Tender Offer false
Security 12b Title Common Stock, par value $0.001 per share
Trading Symbol CRNX
Security Exchange Name NASDAQ
Entity Emerging Growth Company true
Entity Ex Transition Period true
EXCEL 7 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 8 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 9 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 10 FilingSummary.xml IDEA: XBRL DOCUMENT 3.21.2 html 1 96 1 false 0 0 false 0 false false R1.htm 100000 - Document - Document and Entity Information Sheet http://www.crinetics.com//20211020/taxonomy/role/DocumentDocumentAndEntityInformation Document and Entity Information Cover 1 false false All Reports Book All Reports d195018d8k.htm crnx-20211020.xsd crnx-20211020_lab.xml crnx-20211020_pre.xml http://xbrl.sec.gov/dei/2020-01-31 true false JSON 12 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "d195018d8k.htm": { "axisCustom": 0, "axisStandard": 0, "contextCount": 1, "dts": { "inline": { "local": [ "d195018d8k.htm" ] }, "labelLink": { "local": [ "crnx-20211020_lab.xml" ] }, "presentationLink": { "local": [ "crnx-20211020_pre.xml" ] }, "schema": { "local": [ "crnx-20211020.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd", "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd", "https://xbrl.sec.gov/naics/2017/naics-2017-01-31.xsd", "http://www.xbrl.org/lrr/role/deprecated-2009-12-16.xsd" ] } }, "elementCount": 25, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2020-01-31": 2, "total": 2 }, "keyCustom": 0, "keyStandard": 96, "memberCustom": 0, "memberStandard": 0, "nsprefix": "crnx", "nsuri": "http://www.crinetics.com/20211020", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "p", "div", "div", "body", "html" ], "baseRef": "d195018d8k.htm", "contextRef": "duration_2021-10-20_to_2021-10-20", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "100000 - Document - Document and Entity Information", "role": "http://www.crinetics.com//20211020/taxonomy/role/DocumentDocumentAndEntityInformation", "shortName": "Document and Entity Information", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "p", "div", "div", "body", "html" ], "baseRef": "d195018d8k.htm", "contextRef": "duration_2021-10-20_to_2021-10-20", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 0, "tag": { "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag", "terseLabel": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.crinetics.com//20211020/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code", "terseLabel": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.crinetics.com//20211020/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]", "terseLabel": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "xbrltype": "stringItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented. If there is no historical data in the report, use the filing date. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date", "terseLabel": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.crinetics.com//20211020/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "dateItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type", "terseLabel": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.crinetics.com//20211020/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One", "terseLabel": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.crinetics.com//20211020/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address, Address Line Two", "terseLabel": "Entity Address, Address Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.crinetics.com//20211020/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town", "terseLabel": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.crinetics.com//20211020/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code", "terseLabel": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.crinetics.com//20211020/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province", "terseLabel": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.crinetics.com//20211020/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key", "terseLabel": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.crinetics.com//20211020/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company", "terseLabel": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.crinetics.com//20211020/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityExTransitionPeriod": { "auth_ref": [ "r7" ], "lang": { "en-us": { "role": { "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.", "label": "Entity Ex Transition Period", "terseLabel": "Entity Ex Transition Period" } } }, "localname": "EntityExTransitionPeriod", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.crinetics.com//20211020/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number", "terseLabel": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.crinetics.com//20211020/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "fileNumberItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation State Country Code", "terseLabel": "Entity Incorporation State Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.crinetics.com//20211020/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name", "terseLabel": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.crinetics.com//20211020/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number", "terseLabel": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.crinetics.com//20211020/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "employerIdItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number", "terseLabel": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.crinetics.com//20211020/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre Commencement Issuer Tender Offer", "terseLabel": "Pre Commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.crinetics.com//20211020/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r3" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre Commencement Tender Offer", "terseLabel": "Pre Commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.crinetics.com//20211020/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r0" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Security 12b Title", "terseLabel": "Security 12b Title" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.crinetics.com//20211020/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name", "terseLabel": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.crinetics.com//20211020/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r4" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material", "terseLabel": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.crinetics.com//20211020/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol", "terseLabel": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.crinetics.com//20211020/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r6" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications", "terseLabel": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.crinetics.com//20211020/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" } }, "unitCount": 0 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12" }, "r5": { "Name": "Regulation 12B", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r6": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425" }, "r7": { "Name": "Securities Act", "Number": "7A", "Publisher": "SEC", "Section": "B", "Subsection": "2" } }, "version": "2.1" } ZIP 13 0001193125-21-303072-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001193125-21-303072-xbrl.zip M4$L#!!0 ( 'N"5%/TH6CO3 , '\+ 1 8W)N>"TR,#(Q,3 R,"YX M/7)LJ'YV<< -$B6(-",PL\F2A[U(2/.[#:XG'3S3*LG%*]>$H MZ#B 2*'^.8#PXAF5RM#) \C]. #RDY.3-$AW*)5N^QR=]:.T%09M_V/.&3%K M'%YH4YWCG#62D(WZMV%2S 6609-JMT+EMG2V-1PS"W37K$);,X[/BSJ5V&.' M([YY^O?GJZ^A^J(S#P (!2FJ6AL';5U>:1X:YD!,_5/:ZVZ)-7^)%7^=3G$.8< 4SW&B)A^=@6AM=HW&" M+H5-J[0&;@W.)Y&_%>)^"GV7;);0%.I5'CC8;CXO3@F"\FI#K\?7COYX8TP"^^ M32\/7!_K^R-U;*F5KE8MRW/-&W]']?\?5/E)$;?5)966J0*O" 1=-%-2__XD M]37+GF>)]+XG0OWFF?_0ZV!O8;ADJH36' SLG::[1G;M-Q;+/]596',F>2/7 M4>_ G<8AX&Z^GH[<,-N/ZW;[C/5]G.XV"TR,#(Q,3 R,%]L86(N>&ULS9QO M;]LV$,;?%^AWN'EO-J"R+0Z>NT?^G<+(5MY_W"QB>"!"4LZ.>WY_V /"0AY1-C_N MK:07R)#2'L@D8%$0ULB>Q\_O'[U_@?/@]/SBT_@P7V2+.5X,%BOU_WH MCC+)XU6B)&4_Y(L!>%X1/YE^@3^R?W M"?P4_@QIUBEGC,0QV<(Y90$+:1##;='S&[A@81].XA@^ZS2I&I5$/)"HGZO& ME/TWUO_,=/OP^A6 .H],ION.>_ILY"=C,Q-QGXNY:G9X-"A2>H\9F[V4]5&: MX+][]VZ0'BU'2VJ*5>+^X*^KR]OPGBP"3YU_]7J%>1E)QS+=?\G#]"1:- B5 M$?I_7A'FZ5V>/_*._/Y&1KT/NF!^=H(9B2_5%J0>QH+'I*:P/IQ6[^7QR7:I MXLDF(2PBN?(W;1[F4?>"W&6JFKY44I*P/^9\_JEU? M)UQA?S*3B0C"9+=JK$\4%\7.U,IQSY TV&U+QYV(<$HM$R]5+-+O!%\8N\C+<5);>LH)\[[<'O*:"96-"2+Y2BC( MFKS J9\/J3+\4VC_^W[P6/NEM*HN)))<-NT7 \R3A4)>_4W.XV!N"^:3I([ M-+?.#0?;@&D00@+SFS)HZ=98.FBTC*5MMQA0GK&$)MN)*B:"^$)=DC>_DZTM MG!7)'4%:;X77!+6!MD80"=ZL N0E(*T!JDAKC!VV7L:Y>?\88)_R<*5G:*H\ MV/*\F],1QL;&^?ZQ-M#NZR"Q6@B#5FX-*'Z;92XM>\6$\88(RJ,S%IVJ'W>: M4ODDN6,\S59X31 &L 9!;'*S$J!J@"Z"!K&#UHTT6_>/MWSX3.94+Z%9\BE8 M6'-MSNUT\5!AA%?'M%\ZF/1P5PZ/%4"70%HWN.C;L&RP;AX/YPL6SR:U3VH^"A3SN9.P4A+0BY"5!UT0:E>_@ MRS YSS>'-TKG-":?5HL9$\5IA7-Y5*=BMA4N_4RN& M47B&'[S!.(DB94/F7RXI(WZSH3 *=#H0=9;X@<#V@U IBCL$N?Z;8@-T);AF M6"L;9S8, _ ,+RX'8-1V $8O;@!&M@,PVT =\'8NT&%/ M?V:^%C>"/U 6-KSU4Z7Q$K"O,F9B_TDLV@ 8=1U-07;S0P%45,,=!2=6ZN:A M@1_TH;CA,@GBO^FR^=U0L\)+& BS*=,X[$2B#8-!U=$H9)5 E<*\P^G.1MT8 M6'M!^5RAMBE(T 3[W9RN/E5H:ISO'VOUF<(]'21\T^_\6AF'5OP^=SY/:-DL M!H[Z0[_QS3UG#>^O[^=UA&6E 6X^W@9/LQ82HJDXI.I8=QC=]%M&M4G3&+C^ M*6B2$#;AB\6*Y? M ^I;'M.0)I3-K]1Z7- @MB7:E-D1SC4F>%5$&Y"KU) H?I2'0K\UPJY:+O/; MJ&\,>&\$T;-"%!SI9RSU\SCB^N[.?BE1I] 1S!:F^*'(-G ?4D6"7)6!1G#4&W0/!)[\8B#4:'M:CRR5XN=*@/HA;7,R<5! MJ4,JWWZ5XZ3?G35.@Z8Q<)V*0#_P?KM=S+CUTOQ)4D>@FEOGAH-M$#4((?&9 M*T,FW9I-!XV6P;3M%O,:>K8)[Y5GTN21"7-NQ]=2HQ%>'8-Q3=W7P[ZN%A5P M'IEPU[?Q^FK9/-Y[@V<+(N9J@GX3?)W(.PL1?$0=BH[R5,4GWW,7L2K^$4&/*[ M'8%J0[P^#@'^"DUD\C?P6"9_?!(+>T<&3,S;N"CON%1;^G<>Y;MH]IM_U)[_ M 5!+ P04 " ![@E13*58^ > $ "9+@ %0 &-R;G@M,C R,3$P,C!? M<')E+GAM;-V:86_B-AC'WY]TW\'+O=FDA9!P[594>F*TG=!HBX#;IKTYF>0! MK#EV9)L"WWYVB#<"H0>]W12O0D =_Q___?P<$SNY_K!.*7H&(0EG'2]L-#T$ M+.8)8?..MY0^EC$A'I(*LP13SJ#C;4!Z'V[>OKG^QO?1[7W_$?EHH50FVT&P M6JT:R8PPR>E2Z9"R$?,T0+YOZ_J6,P:4P@;=$X993#!%8^OY>]1G<0-U*44C(Y/:J 3Q#$FCB$H) M^[-MWJ;&/GK[!ND_G4DF\]*.9_)1I&,]%;3!Q5S;;;8"*_)V->L#T:J52\*K MJZL@/UJN+TE5;=U &/S^,!C'"TBQKREH:O%>4]I-HOY6[YJ["+8';7U)VC*/ M-.!QGOP3NH6.UC#_^;::;XK\,/);86,M$^_&-+G-JN 41C!#YO/CJ%]J,Q:$ M@2+Q=E3E_,.F'@@*KSGCZ28PHN"6Q\L4F+*?79;<,474IL]F7*1Y5SR49[6] M$##K>+%@:]]&,X;>C72@3^<$4IM,GQJ2I!D%#P4['3GZ;?# MD[W31 MIQ[7,T=W*I7 L2IG@IHQPX4MI'@*M.-5B()_WU97IR Q:;BG>'ZJK3U1V=8N MPZZ(2R&QB&TX_?4 8/DL*&H$&18ZGA\O](QGU3/!T\H4%:WQ2J-<)" Z7A0U M]-GOH4P0+C1X7>*AI=1>>&9<8VJ.P0R$@&2P[?91E[E%/9-*R&M^%4C;\=G3 M_1"8]O4YL/X%-J?".B*N+[0CABV\EF/P[#PSTL?@^167SB=BVI/7']F>X8MO$O'X&UGBQ',B>DN4X\X/9E=M;:^Z*K]6G(_ M.$E.+Q^XR+C($SS6>88>7^JI?]/CR9D@/Q.J[EP_8]]B_M%)S/>$PN,RG8(X MC^FNKNX =[U:6E=.TIK@=3_1R2 SLEW.O@;=T2!UYWC4> &UU702:C=)=*IE M\:&7UQ">![0R0-UA5IJV(,/_"Q' $YH%O2_2]RT2'7"I,_R#9 M^>N0Z@B.T-QS;5FZMJ=C9IBN 'P.O;*FOKS*/BTAUS9NS)TR.EQP=N:Z\%!7 M7U*'7BTMUS9K?M,N%; >3],E*Y9%\E1D1\3UY7;$L(7GVA;,F%,2$T78_$'_ M5 MB#)Y&KDI97VQ5;BTSUS9BA@+,\ -]197?83&WOL73;';Z1/E2A/HR?,EU MP?*]:_LO>WWJ2[D$\>5$*^(XP[7"NZ7KVJ;,&.*E,1I&TPE1].3+S4-=?>D= M>K6T7-MYF0AL'M@;;](I/_EG<$]47TY[1BTDU_96['"[6\<+S.9PSDW=:FU] MD57[M>36CH2H+\<7;5NF?X/&*7MV#/6@[3LV/*CX\ARZFMB>R1UFKLO&8B$+)PI@@5(2^I??[L M*%$/6H_(3IISIK5$X;58[/YV%POP]-=A/R"/3"HNPK."4ZH4" L]X?/P_JR0 MQ-WB48'\>O[C#Z>]&"I"Y5#5?,;/"KTXCFKE\K C@Y)B7NE>/):AH.Q6W$JQ MXA3WG8*MGJAB/(J8&K?I4M4I"7E?3DL6- I%&";]<9/!8%#20V$S/Y9E;%>& M2D6HQ23WTG;#@(2AJHK9)_& M(#W8TT&QXA;=PTPG19"-J8Y265G6SU%&&'!P_M149[B(I?Z,C-K*AV53:*OF M2PK*>T$+/J,^?L8\#MCY4?'WT[+Y"K_U64P)]E!D?R7\\:Q0%V',PKC8!O$L M$,\\G15B-HS+ND=2QG9EVRDAY+0C_-'YJ<\?B8I' 3LK^%Q% 1VA"K#".3GE MPQI69])^Y[[/0O,=JMP8^2'#D5M_.TU>>X8QD728!R9B"9U3EFM(:!V,1C0(U M1)"S@N+]*$#!T;_U))*"FEY,];DT5'Y:3*4G!2[1RJ#Q#'!T?EJ>GH^=_=2, M];,2B32/6H%JEMUZ]59@=]J,Z<4;/W(??^AR)HDF@2U4[_KU[],+-ML8J5[8 M?P0K*OSQ(VBVC"]IS,XGM*4M)V436OV-CQ..4I[HRY.>%>.:N!9=!4 M^,CH*[8JTH#?AS4/YL)D8;I\P/VX5SLJ'?#P)%,W8-WXI$_E/0^+^+U&:!*+ M]!?)[WOV)^PN2CM#T"SVF"X%:QV-NXA%5,L\=D0*--M%3HA\Q,@75B:HN)_LYIS-'[N MTCX/1K4V[S-%;MB -$6?AB>Z;&#H[HC /UFP/'_<7+<;EZ35OF@W6OGD5%Z( MG%:C_D?SNGW=:)&+FTO2^%3_[>+F?8/4;S]^O&ZUKF]OOHA&=QLT_DE5#WS" M6(1[Y+)4+Q&WCUD1?O$8&,^!I!$8DSPOXE)X M"3H1&4]F=4NMO:1I$WU:1E+.7R7F621F*SH.*-1LW+1)LW%WVVQ_?\^EH!!2QL'!^Z\6B QZF6]DCV&X>35YA9/LP MXE:W(6RYHF.BP":[YPI#_O@&2M8V+?5TUX7<]2@(D<<2>(*@=8]@$[X'%'?3Y_M6':NG@@"&BE62[\\+2,9@4*_SG## MJ51^MKRK52R9M4H:[B%ATGSXTU'D?O5GW "(_9G21R:U%ECNF@DOK&G[<=?H M)Z5Y<9/9#N&/I5VF52)ZSXH=R>@#;GARG]7HHP )69EQCEZZZ7%)1IK(E#C5 MM""1F;F 3 "%67]X5GN70A< C)!@(C5&M6*P6W61A+$E4Q2&5^KOZS\'#CD,,P^8H'#,K ^F^P0>@4]X\. MCO9S.?8],ZY-A]=V>\W3G-J0B^YAHXU178^!S:?K0E9=_4[F\E_-[1 M^(#!RBW$")+\"T($Y7,3Q8CN6GZ)\PST36&9)E/>TY#_K9]WC:W])M5DIR[Z M?:XP87G:D:1\CH!!C*SO?ML:OG-=:I9:)=+H1X$8,6GHGU;:13/12@9_T%GY M@E!R*^[L$A"Z\'W)E+(?'\"A=-8&(*?BNBYY1V4(U-5I. *N- 7U9^%H+S]* MS2/&79N8=X%_3]ZXWUY"OOP*7A M.CN[;0>I#AR!2B&GRQ*6.13>">@S^ ^/-G'@SH]=9^G.Q+5(J'U<-\)V7S==B. V!E3.]+! D&DP0D MC2#W]P@-?=)F 8N0 Q;SLS5QG6Q5O6^7;AK\\N;(==Z>*'(G0:=X1 /2&#(O MB?DC([==L"),O6X>/,\F^S+M!$#J,>]![PG3"( JDAQ]P(X8D@X+Q(!PLV%\ M!<"V7'5T$D7+,NGR (6"*\+Q1(G/?-P35[R?!#$-F4A4,"(*-$9U1WH$VT!T M@%]:D12QF]69_:<$.I(@B:.TK"L"H!(;(LIR=+%4+5>8#C?>;]G6?HHS26_7 M*IF=E?D=G)D=GM4BEMD@Q Q0_?EDH>N7!W1_2A[#FJ'7FH36R5-?; L[0@0= M"LL5@W0AEX\A9#N9Q\)E?O!LH$2F5Y1\L<6:.?%0.+?\ 9D&4*B3+*GF8"0 M5-T#*Z$S.19,K>PX;TG]JDG<_4H)*D[BE3Q7^55LUQ3;%L"P!PP/[S\"A@&0 M!?_',CMA!G1MN#$OL$L!W:G2HN.FF#Z1[:FD82K92WMSJY62Z7$WX_*\*L$V ME>!.,L1M/%6GST*@Z97@9:WOKGY'RK!4,H%K12_#ME3BER'^"@KD%]V=SNYV M5\@"KU M4GF?39GXE9-Z;4E1>;]Z\JXUZD/1CGJQ/-T+K-=S\.G&'KK2 LZL83-9-[ ! MH)#P\\103-NK[^T(B[6-(\?M:,5?_^0=^!S M58LO(<]$E%)'FF0,/)3!<3! M(1%>".K]\XZKY/'+ZKI1M?69U;SY])TP(A6'J''WI\ /A@^F3'S*XZ M5P38#-XZ#GI/[J48Q#UTV"/<::>*^*S+0W/BTVQT5@[(_$GRR0'R_;$7CO+P M]L1L>E8.=O'4QHK>OMLICC>>5CNU/COH:A$ CK-;6IJ"V\ZZ-')XO"3WFS9[ MKUO53:-G"4(/%P2AS\N2Z^X3PK<'(K=0DOE<:J@'AAUNHU//P_"16 MQ@OLG8[^T:J,G( MVKSLCS^ C5NH&JP_IQGX4\8GZS!8'/#)@@$=*70ZH7.\NS_VWR"F%K+VYEC_ M.TDG% VG-LW*EHBG<][;O=O[XP\O=UH$\"%F?<-^MU1Q2Z3)5!+$.CE\"TIL MMY/P<,+56$OK E!#:U\^>AUN)7O^]-4.LH-*CP<@W,J)A6W]Y)P@O*0%:2>V M:)@CTJ%SD(0T 7X"P.%P MD60![P.OY<@,KXA*.O]%#PA@3X,ILT=&,\#I!4+9-+W' +F8*I$+& 0P%M=S M#V8Z&;-/1\3GN--*NE+TS?$$4Z09,H!ID ["?]U@&TCAX?B=(C@CS1*4?X*BCZ$*3!MM&TS= M9S A/Q6A+@^8GTH63@PL4204L\NL+9&9D'.THC>UAZRB?LO3@\&GC:L@KYLI(?LH F/\&02GAEA,=,#JP2"9&K'?G+ECIX%LJZ$'(!C4/P@Q /.OC41OQ?#(P^P6B/C M2"1&:3)*@%X$33UZ+66P*')RGQ+]*IB 31Z##^$2$6BXRZ*@/BZ4$=0!L6-< '0@!B+)! M_!)IX2KG#XJR&20^6]A["K"^053L?!Y:EV$D,T.H%.OR25$]D01^JKJ&N8BF M!O]0LJ&:47L0ZLDB&J:;TTYH!*( _,$Q^E&OQ]DC\TNH20FLA;2F<1X^!7)_ MK#@YB^XG#!%<^]5)Z!3$H5%JRP/>TPW682W'6!%J(\/\O10X)YVJ442 M$S099HHU$@E\QY"V"AIVL-^5EF1*8E:W-+HSL%H,FF-=VQ)%@TM_; !P75,> MGN@V0D?+AAD^4Y[D'>9GP Q?L8)#611N0D5R!0HA9&K+<6:^O7^LLJ*(Z 24 MF?4!-=:YR6W$7'DP;O2./2^";>4V6+6-# !Y"N['E?X8@4 +0BB=T M$-D$*QV,[ZY"!QRM?LPEBT>H>$8I#"O1NQFW3KG"4;=\EI$ 1;M 94=M+GC M$X@IP^XDB&X\M90?X,.RIHD10']B!H\/K*UZRL&>LQ!D+CNT[)TUV_#3%P09 M;DH\OBUL$B3!9/1_KY'2RY^K;UV_O[EH_]%LM)[=?=EH%NNW'SYF=I%F314?"TSF'NW'Z9 M/1%SF":I9\LWSGL?;+W'ZMNI3/ID4L^:XLK);.!+0VK$ON7#;DB,7_7QQ>F1 MU4\M;*OGIU,K2]]9\>1]V@R#Y_F;[@&Z6+2 X&PYN&JH2>%9P=V@[DLE15]^ M\9ZMY_5RWTOV3=H277^" MY\][:_X[9_NS^7[ZD*72+R8U85B/L^[ $ "9+@ %0 M @ %@"@ 8W)N>"TR,#(Q,3 R,%]P&UL4$L! A0#% M @ >X)44XTLC. 8$ GUP X ( !